The most common form of aggressive lymphomas are diffuse large B-cell lymphoma (DLBCL), accounting for 30--40% of newly diagnosed non-Hodgkin\'s lymphomas (NHL) ([@bib15]). For several years, standard immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is administered, and the disease can be considered potentially curable. Nevertheless, approximately one-third of patients with advanced-stage DLBCL will still be refractory to therapy or will relapse ([@bib8]).

Currently, clinicians rely on prognostic schemes that imply clinical risk factors to predict the risk for disease progression, relapse, and death of patients with aggressive NHL. One of the most commonly used schemes of rating, the International Prognostic Index (IPI) for lymphomas, involves five features: age, tumour stage, serum lactate dehydrogenase (LDH) concentration, performance status, and the number of extranodal disease sites. The IPI distinguishes four risk groups with different 5-year overall survival (OS), ranging from 26% to 73% ([@bib28]). In the era of rituximab, a revised IPI (R-IPI) has been introduced, showing superior prediction in outcome of DLBCL patients, treated with standard immunochemotherapy ([@bib27]).

Recently, the development of molecular signatures, identified through gene expression profiling (GEP), has helped to identify new therapeutic targets to complement standard therapy and proved to be useful in adding prognostic information ([@bib2]). GEP has revealed three subtypes of aggressive lymphoma, discerning in developmental stage and usage of different oncogenic pathways. Patients with germinal centre B cell-like DLBCL have a 5-year survival rate of 60%, as compared with a rate of \<40% for patients with activated B cell-like DLBCL, whereas a third, smaller group lies in between ([@bib26]). However, rating by molecular markers is associated with high costs, laboratory efforts, and time-consuming procedures and is not routinely available in most laboratories. Therefore, the search for cheap and easily applicable prognostic markers that might help to improve the prognostic accuracy of existing models is needed.

The association between inflammation and cancer has been previously described ([@bib6]). Various inflammatory parameters have been linked with cancer development and progression ([@bib25]; [@bib9]; [@bib21]; [@bib24]; [@bib20], [@bib19]). One of the most commonly used inflammatory markers in routine diagnostic is the C-reactive protein (CRP), an acute phase protein, produced by the liver after interleukin-6 and other cytokine stimuli. Its prognostic role in various solid and hematological cancer types has been demonstrated recently ([@bib3]; [@bib13]; [@bib10]; [@bib31]). In DLBCL, only a few small-scale studies that include some of them before the rituximab era have been reported ([@bib7]; [@bib14]; [@bib12]; [@bib5]). Therefore, in the present study we aimed to validate the prognostic significance of the pretreatment CRP level in a large middle European bicentre study including two cohorts of patients with DLBCL and test its value to improve the predictive ability of the well-established R-IPI prognosis score.

Patients and methods
====================

This retrospective bicentre study includes data from 477 patients who were diagnosed with DLBCL according to the 2008 World Health Organisation ([@bib4]) criteria between January 2004 and April 2013. Of the 477 patients, 288 patients (cohort 1) were diagnosed and treated at the Division of Hematology at the Medical University of Graz and 189 patients (cohort 2) were diagnosed and treated at the third Medical Department at the Paracelsus Medical University Salzburg in Austria. All of the clinico-pathological data are retrieved from medical records from either of the institutions, as well as from pathology reports of the Institute of Pathology at the same institution. Clinico-pathological parameters include histologically confirmed DLBCL, gender, age, and Ann Arbor stage. The laboratory data, including whole blood counts, derived neutrophil-lymphocyte ratio (dNLR), and CRP, were obtained by prediagnosis exploration 1--7 days before histological-proven diagnosis. A preoperative plasma CRP level is routinely measured at our institutions for nearly all patients who underwent a consecutive chemotherapeutic regimen. Of note, for 23 of the 311 patients in cohort 1 (7%) and 24 of the 213 patients in cohort 2 (11%), CRP or other values were not available, and therefore these patients had been not included into the final analysis. Patients were treated by standard R-CHOP regimen, CHOP-like, or third-generation anthracycline-containing regimens but all received a combination, including the monoclonal antibody rituximab. Posttreatment surveillance included routine clinical and laboratory examination. The predominant imaging method used was computer tomography. Follow-up evaluations were performed every 3 months during the first 5 years and annually thereafter. Patients were excluded in case of seropositivity of HIV or missing laboratory parameters at diagnosis. Dates of death were obtained from clinical records, the central registry of the Austrian Bureau of Statistics, or by telephone calls to their relatives. Five-year OS is defined as the time (in months) from the date of diagnosis until death due to any cause within the follow-up period. Five-year disease-free survival (DFS) is defined as the time (in months) from the date of diagnosis until the recurrence of the disease being confirmed radiologically or histologically. The study was approved by the local ethical committee of the Medical University of Graz (No. 25-434 ex 12/13) and by the Ethics Committee of the provincial government of Salzburg, Austria (415-EP/73/127-2012).

Statistical analyses
--------------------

The primary end point of the study was 5-year OS; the secondary end point was 5-year DFS. In a first step, an optimal cutoff value for CRP to differentiate between survival and death in cohort 1 from Graz was determined by applying receiver operating curve (ROC) analysis as previously reported ([@bib1]). Using this cutoff value of 15 mg l^−1^ for the whole cohort, the association between CRP levels and clinico-pathological parameters was evaluated by non-parametric tests (chi-square test, Mann--Whitney *U*-test). Kaplan--Meier curves were used to show an association between CRP levels with OS and DFS, and log-rank test was used for comparison. Backward stepwise multivariate Cox proportional analysis was performed to determine the influence of clinico-pathological variables, meaning whether they are significantly associated with clinical outcome in univariate analysis of 5-year OS and 5-year DFS. Hazard ratios (HRs) estimated from the Cox analysis are reported as relative risks with corresponding 95% confidence intervals (CIs). Patients were categorised according to the R-IPI prognosis risk groups. Harrell\'s concordance index (c-index) was calculated using the individual R-IPI groups followed by the addition of the CRP levels ([@bib11]). All statistical analyses were performed using the Statistical Package for Social Sciences version 17.0 (SPSS Inc., Chicago, IL, USA) or the STATA statistical software (College Station, TX, USA). A two-sided *P*\<0.05 was considered statistically significant.

Results
=======

Overall, 190 (39.8%) male and 287 (60.2%) female patients with DLBCL were included in the study cohort. The median age at diagnosis was 68 (interquartile range 59--77) years. The Ann Arbor tumour stage was defined as stage I in 127 (26.6%) patients; stage II in 121 (25.4%) patients, stage III in 102 (21.4%) patients, and stage IV in 127 (26.6%) patients. Regarding the R-IPI, 44 (9.2%) had a very good R-IPI, 249 (52.2%) had a good R-IPI, and 184 (38.6%) patients were classified as a poor R-IPI. Overall, 156 (32.7%) patients died, and 184 (38.6%) had disease recurrence by their most recent follow-up visit. Two hundred and seventy (56.6%) patients received a therapy with R-CHOP, 175 (36.7%) received CHOP-like, and 32 (5.2%) received another therapy. The median number of administered therapy was six cycles.

Using ROC analysis, a cutoff value of 15 mg l^−1^ for CRP was determined as optimal to discriminate between patients\' survival and death in the larger cohort 1. Applied on the whole cohort of 477 patients, a highly significant association (*P*\<0.001, log-rank test) between high CRP levels and poor OS could be determined ([Figure 1](#fig1){ref-type="fig"}). A negative prognostic impact of high CRP levels for 5-year DFS could also be identified (*P*\<0.001, log-rank test, [Figure 2](#fig2){ref-type="fig"}).

Moreover, the association between CRP levels and other clinico-pathological factors was tested, and a correlation to advanced tumour stage (*P*\<0.001) and a poor R-IPI (*P*\<0.001) was observed. No association of CRP with age or gender was found (data not shown). There was neither a correlation of the CRP levels and the number of administered therapy cycles (spearman R=0.33, *P*=0.576) nor a significant association between CRP levels and completed therapy cycles (defined as ⩽6 cycles, *P*=0.754).

Univariate Cox proportional analysis identified gender (*P*=0.026), older age (\<60 *vs* ⩾60, *P*\<0.001), high tumour stage (stage I+II *vs* stage III+IV, *P*\<0.001), elevated CRP (\<15 mg l^−1^ *vs* \>15 mg l^−1^, *P*\<0.001), dNLR (\<4 *vs* \>4, *P*=0.018), and high R-IPI (very good and good *vs* poor, *P*\<0.001) as prognosticators of poor outcome for patients\' 5-year OS ([Table 1](#tbl1){ref-type="table"}). To determine the independent prognostic value of CRP, a multivariate analysis, including gender, age, tumour stage, R-IPI, and CRP levels, was performed. We identified age (*P*=0.015), R-IPI (*P*=0.003), and high CRP (*P*=0.031) as independent prognostic factors for 5-year OS ([Table 1](#tbl1){ref-type="table"}).

Regarding the 5-year DFS, univariate analysis showed statistical significance for older age (\<60 *vs* ⩾60, *P*\<0.001), high tumour stage (stage I+II *vs* stage III+IV, *P*\<0.001), elevated CRP (\<15 mg l^−1^ *vs* \>15 mg l^−1^, *P*\<0.001), and high R-IPI (very good +good *vs* poor, *P*\<0.001) as prognosticators of poor outcome ([Table 2](#tbl2){ref-type="table"}). In the multivariate analysis, we identified a high age (*P*=0.002), high tumour stage (*P*=0.031), and high CRP (*P*=0.002) as independent prognostic factors for 5-year DFS ([Table 2](#tbl2){ref-type="table"}).

Finally, regarding 5-year OS, the c-index of the R-IPI prognostic model was 0.75 compared with 0.79 when CRP level was supplemented.

Discussion
==========

CRP has been identified as a prognostic variable in various solid as well as hematological malignancies yet. Increased CRP concentrations have been found to be associated with poor OS in many types of cancer, including colorectal carcinoma, prostate cancer, soft tissue sarcoma, pancreatic cancer, and small cell lung cancer ([@bib13]; [@bib10]; [@bib31]; [@bib30], [@bib29]).

The role of CRP in the prognosis of non-Hodgkin lymphoma patients had also been well studied in the pre-Rituximab era ([@bib18]; [@bib14]). More recently, the correlation between CRP, IPI, and long-term survival in DLBCL was investigated but only in a small group of 94 Chinese patients ([@bib5]).

Hence prognostic significance for increased CRP in DLBCL has been indicated; however, a validation in a large middle European cohort with different genetic background is still missing. In the present study, a significant association between elevated CRP and poor outcome of 477 DLBCL patients at two Austrian centres could be confirmed. Univariate analysis, as well as multivariate analysis, identified the pretreatment CRP level as a useful prognostic marker of 5-year OS and 5-year-DFS. Furthermore, by integrating the CRP levels in the well-established R-IPI score improved the predictive ability of this score by 4%. Beyond the results of our study that focuses on the CRP levels before treatment initiation, [@bib12] identified the early--mid treatment CRP level as a reliable marker in NHL patients to predict DFS and OS. Patients who did not achieve low early--mid treatment CRP levels had earlier disease progression or earlier relapses and also appear to have an inferior OS. However, \<100 patients were included in this study, and further confirmation in larger series is needed.

Our findings are in line with previously reported data also demonstrating a prognostic value for CRP levels in various other hematological disorders. For instance, in extranodal natural killer/T-cell lymphoma, a heterogeneous histopathological subtype of NHL with increased incidence in Asia, high CRP levels were found to impair the natural course of disease ([@bib17]). In this study, beside lower rates of complete remissions, inferior DFS and inferior OS were found in patients with high pretreatment CRP levels. Therefore the authors constructed a new prognostic model, including CRP, age, hypoalbuminemia, and elevated LDH levels, to identify different prognostic subgroups ([@bib17]).

The reason for the general poor prognosis associated with higher CRP levels remains elusive. Recently, [@bib33] demonstrated that CRP enhances cell proliferation under stressed conditions and protected myeloma cells from chemotherapy drug-induced apoptosis by binding to activating Fc*γ* receptors, activating PI3K/Akt, ERK, and NF-kappaB pathways and inhibiting caspase cascade activation induced by chemotherapy drugs. Whether these or other mechanisms may have a role in DLBCL has to be clarified.

Apart from CRP, other inflammatory markers have been found to be involved in the development and progression of lymphoma. [@bib24] conducted a prospective study of 67 serum immune and inflammatory markers to identify possible predictors of NHL. A significant association between the elevated levels of BCA-1, sTNFR2 and sVEGFR2 and increased risk of lymphoma development, several years after blood collection, could be shown.

Nevertheless, comparing the costs and availability of these markers, CRP seems to be more convenient for routine use. Interestingly, using the previously published dNLR ([@bib32]) we could not detect an independent value of this blood ratio when exploring this parameter in the multivariate analysis for both cohorts. This means that the previously published cutoff values may be not optimal to generally apply for all cohorts. In addition, it seems that CRP outperforms dNLR as a prognosticator, which should also be considered in future prospective trials. Several other blood-based inflammatory parameters have been suggested to have an important role in NHL cancer progression and prognosis ([@bib24]; [@bib16]; [@bib32]; [@bib22], [@bib23]). These include the Glasgow prognostic score, the fibrinogen levels, the neutrophil--lymphocyte ratio, and the lymphocyte--monocyte ratio. All these studies have been performed on retrospective data sets, including in part several hundreds of patients. Future prospective trials should assemble a panel of these markers and evaluate the prognostic value of these parameters for differentiating patients with varying clinical outcome. Each of these parameters can add additional prognostic value and supplement established risk scores such as the R-IPI or the recently proposed NCCN-IPI to improve prediction of individual patients\' outcome ([@bib27]; [@bib34]).

Together with the whole blood count and differential leukocyte count, CRP is routinely measured in most medical laboratories, which make an implementation for clinical routine more easily. Our study is not without limitations. As with all retrospective studies, a selection bias cannot be excluded. Taken together, the role for pretreatment CRP levels in risk stratification should be strongly considered. In our opinion, the integration in preexisting prognostic risk models for a refined new risk stratification score should be prospectively evaluated. In the end, an improvement of the existing risk stratification tools could result in better treatment choices for DLBCL patients.
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![**Kaplan--Meier curves for 5-year DFS regarding low (\<15 mg l^−1^) *vs* high (\>15 mg l^−1^) CRP levels (*P*\<0.001).**](bjc2014277f2){#fig2}

###### Univariate and multivariate analysis of clinico-pathological parameters for the prediction of 5-year OS in patients with diffuse large B-cell lymphoma (*n*=477)

                                        **Univariate analysis**   **Multivariate analysis**                       
  ------------------------------------- ------------------------- --------------------------- ------------------- -------
  **Gender**                                                                                                      
  Female (*n*=287)                      1 (referent)              0.026                       1 (referent)        0.212
  Male (*n*=190)                        0.691 (0.50--0.957)                                   0.81 (0.58--1.13)    
  **Age at diagnosis (years)**                                                                                    
  \<60 (*n*=180)                        1 (referent)              \<0.001                     1 (referent)        0.015
  ⩾60 (*n*=297)                         2.86 (1.90--4.3)                                      1.77 (1.12--2.81)    
  **Clinical stage (Ann Arbor)**                                                                                  
  I and II (*n*=248)                    1 (referent)              \<0.001                     1 (referent)        0.802
  III and IV (*n*=229)                  1.86 (1.34--2.6)                                      1.06 (0.68--1.65)    
  **R-IPI**                                                                                                       
  Very good+good (*n*=293)              1 (referent)              \<0.001                     1 (referent)        0.003
  Poor (*n*=184)                        2.86 (2.06--3.98)                                     2.02 (1.28--3.21)    
  **CRP**                                                                                                         
  \<15 mg l^−1^ (*n*=266)               1 (referent)              \<0.001                     1 (referent)        0.031
  ⩾15 mg l^−1^ (*n*=211)                2.43 (1.74--3.39)                                     1.51 (1.04--2.20)    
  **dNLR[a](#t1-fn1){ref-type="fn"}**                                                                             
  \<4 (*n*=367)                         1 (referent)              0.018                       1 (referent)        0.205
  ⩾4 (*n*=85)                           1.58 (1.08--2.31)                                     1.28 (0.87--1.89)    

Abbreviations: CI=confidence interval; CRP=C-reactive protein; dNLR=derived neutrophil to lymphocyte ratio; HR=hazard ratio; OS=overall survival; R-IPI=revised International Prognostic Index.

25 cases had missing laboratory values.

###### Univariate and multivariate analysis of clinico-pathological parameters for the prediction of 5-year DFS in patients with diffuse large B-cell lymphoma (*n*=477)

                                        **Univariate analysis**   **Multivariate analysis**                       
  ------------------------------------- ------------------------- --------------------------- ------------------- -------
  **Gender**                                                                                                      
  Female (*n*=287)                      1 (referent)              0.754                       1 (referent)        0.269
  Male (*n*=190)                        0.94 (0.64--1.39)                                     0.80 (0.54--1.19)    
  **Age at diagnosis (years)**                                                                                    
  \<60 (*n*=180)                        1 (referent)              \<0.001                     1 (referent)        0.002
  ⩾60 (*n*=297)                         2.79 (1.63--4.76)                                     2.51 (1.42--4.44)    
  **Clinical stage (Ann Arbor)**                                                                                  
  I and II (*n*=248)                    1 (referent)              \<0.001                     1 (referent)        0.031
  III and IV (*n*=229)                  2.29 (1.53--3.41)                                     1.79 (1.05--3.03)    
  **R-IPI**                                                                                                       
  Very good+good (*n*=293)              1 (referent)              \<0.001                     1 (referent)        0.137
  Poor (*n*=184)                        2.80 (1.89--4.16)                                     1.50 (0.88--2.56)    
  **CRP**                                                                                                         
  \<15 mg l^−1^ (*n*=266)               1 (referent)              \<0.001                     1 (referent)        0.002
  ⩾15 mg l^−1^ (*n*=211)                2.33 (1.58--3.45)                                     1.91 (1.28--2.85)    
  **dNLR[a](#t2-fn1){ref-type="fn"}**                                                                             
  \<1.8 (*n*=141)                       1 (referent)              0.214                       1 (referent)        0.434
  ⩾1.8 (*n*=311)                        1.32 (0.85--2.05)                                     1.20 (0.76--1.87)    

Abbreviations: CI=confidence interval; CRP=C-reactive protein; DFS=disease-free survival; dNLR=derived neutrophil to lymphocyte ratio; HR=hazard ratio; R-IPI=revised International Prognostic Index.

25 cases had missing laboratory values.
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